clinical trial · NCT07231419
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated·phase3·recruiting·n = 734
Diabetic Peripheral Neuropathic PainSuzetriginePlacebo (matched to SUZ)
brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
started
Nov 21, 2025
primary completion
Apr 6, 2027
completion
Apr 6, 2027
last updated
May 19, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol